Dimensional Fund Advisors LP Grows Stock Holdings in Harrow, Inc. $HROW

Posted by Francis Steltz on Aug 7th, 2026

Dimensional Fund Advisors LP grew its position in Harrow, Inc. (NASDAQ:HROW – Free Report) by 56.4% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 579,520 shares of the company’s stock after buying an additional 208,972 shares during the period. Dimensional Fund Advisors LP owned 1.55% of Harrow worth $20,428,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Bank of America Corp DE raised its stake in shares of Harrow by 266.8% during the 2nd quarter. Bank of America Corp DE now owns 213,448 shares of the company’s stock worth $6,519,000 after acquiring an additional 155,258 shares in the last quarter. Invesco Ltd. lifted its position in Harrow by 967.6% during the second quarter. Invesco Ltd. now owns 150,948 shares of the company’s stock valued at $4,610,000 after acquiring an additional 136,809 shares during the last quarter. UBS Group AG boosted its stake in Harrow by 82.0% in the fourth quarter. UBS Group AG now owns 222,362 shares of the company’s stock valued at $10,896,000 after acquiring an additional 100,160 shares in the last quarter. Russell Investments Group Ltd. boosted its stake in Harrow by 110,583.1% in the third quarter. Russell Investments Group Ltd. now owns 98,508 shares of the company’s stock valued at $4,746,000 after acquiring an additional 98,419 shares in the last quarter. Finally, FirstWave Capital Management LLC purchased a new position in Harrow in the fourth quarter worth $4,604,000. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Harrow Stock Up 1.3%

HROW stock opened at $39.92 on Friday. The firm has a 50 day moving average of $40.23 and a 200 day moving average of $40.12. The stock has a market capitalization of $1.49 billion, a PE ratio of -97.36 and a beta of 0.28. The company has a quick ratio of 2.30, a current ratio of 2.48 and a debt-to-equity ratio of 10.30. Harrow, Inc. has a 52 week low of $28.54 and a 52 week high of $54.85.

Harrow (NASDAQ:HROW – Get Free Report) last released its earnings results on Monday, May 11th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.31). Harrow had a positive return on equity of 19.59% and a negative net margin of 5.57%.The company had revenue of $44.20 million for the quarter, compared to analysts’ expectations of $52.43 million. During the same period in the prior year, the firm posted ($0.38) EPS. Sell-side analysts forecast that Harrow, Inc. will post 0.29 earnings per share for the current year.

Insider Buying and Selling at Harrow

In related news, Director Adrienne L. Graves acquired 1,000 shares of the company’s stock in a transaction dated Monday, May 18th. The shares were purchased at an average cost of $31.07 per share, with a total value of $31,070.00. Following the completion of the acquisition, the director directly owned 1,000 shares of the company’s stock, valued at $31,070. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Andrew R. Boll bought 3,500 shares of the business’s stock in a transaction that occurred on Thursday, May 14th. The stock was purchased at an average cost of $29.90 per share, for a total transaction of $104,650.00. Following the completion of the transaction, the chief financial officer owned 814,679 shares in the company, valued at $24,358,902.10. This trade represents a 0.43% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders own 12.80% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on HROW. BTIG Research reaffirmed a “buy” rating and set a $63.00 price target on shares of Harrow in a research report on Tuesday, July 21st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Harrow in a report on Monday, July 20th. Wall Street Zen cut Harrow from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Cantor Fitzgerald dropped their target price on Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $69.43.

Read Our Latest Stock Report on Harrow

About Harrow

(Free Report)

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.